Active, not recruitingPhase 2NCT04428476

Open-label Extension of the HOPE-2 Trial

Studying Duchenne muscular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Capricor Inc.
Principal Investigator
Craig McDonald, MD
UC Davis
Intervention
Deramiocel (CAP-1002)(biological)
Enrollment
13 enrolled
Eligibility
10 years · All sexes
Timeline
20202022

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04428476 on ClinicalTrials.gov

Other trials for Duchenne muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Duchenne muscular dystrophy

← Back to all trials